Tumor immune surveillance defect of X-linked severe combined immunodeficiency is not Epstein-Barr virus specific

Pediatric Blood and Cancer

Volumn 51, Issue 5, 2008, Pages 706-709

  Mustillo, Peter ^a   Bajvva, Rajinder P S ^a   Termuhlen, Amanda M ^a   Nicol, Kathleen ^a   Scherzer, Rebecca ^a   Jaffe, Ronald ^b   Filipovich, Alexandra H ^c   Gross, Thomas G ^a  

^a NATIONWIDE CHILDREN S HOSPITAL   (United States)

^b CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^c CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

EBV; SCID; Tumor immune surveillance

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARAGINASE; CYCLOPHOSPHAMIDE; FLUDARABINE; RITUXIMAB; THYMOCYTE ANTIBODY; VINCRISTINE; VIRUS ANTIGEN;

ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; CASE REPORT; CELL FUNCTION; CELL PROLIFERATION; CONTROLLED STUDY; EPSTEIN BARR VIRUS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; IMMUNOSURVEILLANCE; INFANT; MALE; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TREATMENT RESPONSE; TUMOR IMMUNITY; X LINKED SEVERE COMBINED IMMUNODEFICIENCY;

ANTINEOPLASTIC AGENTS; BONE MARROW TRANSPLANTATION; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOLOGIC SURVEILLANCE; INFANT; LYMPHOMA, B-CELL; MALE; SEVERE COMBINED IMMUNODEFICIENCY;

EID: 52249112227     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21651     Document Type: Article

References (9)

1. Filipovich AH, Gross TG. Immunodeficiency and Cancer, Chapter 16. Clinical oncology, 3rd edition. WB Saunders Company, Philadelphia, PA, 2004.
2. Brandau O, Schuster V, Weiss M, et al. Epstein-Barr virus-negative boys with non-Hodgkin lymphoma are mutated in the SH2D1A gene, as are patients with X-linked lymphoproliferative disease (XLP). Hum Mol Genet 1999;8:2407-2413.
3. Strahm B, Rittweiler K, Duffner U, et al. Recurrent B-cell non-Hodgkin's lymphoma in two brothers with X-linked lymphoproliferative disease without evidence for Epstein-Barr virus infection. Br J Haematol 2000;108:377-382.
4. Trahair TN, Wainstein B, Manton N, et al. Rituximab for lymphoproliferative disease prior to haematopoietic stem cell transplantation for X-linked severe combined immunodeficiency. Pediatr Blood Cancer 2008;50:366-369.
5. Grulich AE, Vajdic CM, Cozen W. Altered immunity as a risk factor for non-Hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev 2007;16:405-408.
6. Okano M, Gross TG. Advanced therapeutic and prophylactic strategies for Epstein-Barr virus infection in immunocompromised patients. Expert Rev Anti Infect Ther 2007;5:403-413.
7. Rooney CM, Smith CA, Ng CYC, et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 1998;92:1549-1555.
8. Cohen JM, Sebire NJ, Harvey J, et al. Successful treatment of lymphoproliferative disease complicating primary immunodeficiency/ immunodysregulatory disorders with reduced-intensity allogeneic stem-cell transplantation. Blood 2007;110:2209-2214.
9. Klein G, Klein E. Surveillance against tumors - Is it mainly immunological? Immunol Lett 2005;100:29-33.